Advertisement
Advertisement
CRBP
Corbus Pharmaceuticals Holdings, Inc.
8.06
USDSponsored
+0.04
+0.52%
Mar 06, 15:59 UTC -5
Closed
After-Market
8.09
+0.02
+0.29%
CRBP Earnings Reports
Positive Surprise Ratio
CRBP beat 21 of 40 last estimates.
53%
Next Report
Next Week
Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.70M
/-$1.60
Implied change from Q3 25 (Revenue/ EPS)
--
/-15.79%
Implied change from Q4 24 (Revenue/ EPS)
--
/+105.13%
Corbus Pharmaceuticals Holdings, Inc. earnings per share and revenue
On Nov 12, 2025, CRBP reported earnings of -1.90 USD per share (EPS) for Q3 25, missing the estimate of -1.74 USD, resulting in a -9.11% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.39% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -1.60 USD, with revenue projected to reach 1.70 million USD, implying an decrease of -15.79% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.37
Actual
$0.26
Surprise
-30.87%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.50%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.04
Actual
$0.06
Surprise
+33.63%
Bioventus Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.21
Actual
$0.24
Surprise
+9.69%
Altimmune, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.27
Surprise
-10.16%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.26
Surprise
-92.31%
OmniAb, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.11
Surprise
-21.82%
Profound Medical Corp. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.27
Surprise
-0.26%
MediWound Ltd.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.56
Surprise
+13.08%
Cumberland Pharmaceuticals Inc
Report Date
Mar 03, 2026 For Q4 25
Estimate
-Actual
-$0.01
Surprise
-
FAQ
What were Corbus Pharmaceuticals Holdings, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Corbus Pharmaceuticals Holdings, Inc. reported EPS of -$1.90, missing estimates by -9.11%, and revenue of $0.00, 0% as expectations.
How did the market react to Corbus Pharmaceuticals Holdings, Inc.'s Q3 2025 earnings?
The stock price moved up 7.39%, changed from $10.42 before the earnings release to $11.19 the day after.
When is Corbus Pharmaceuticals Holdings, Inc. expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Corbus Pharmaceuticals Holdings, Inc.'s next earnings report?
Based on 12
analysts, Corbus Pharmaceuticals Holdings, Inc. is expected to report EPS of -$1.60 and revenue of $1.70M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement